These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 7853725

  • 21. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [Abstract] [Full Text] [Related]

  • 22. The development of resistance to a potent lipolysis inhibitor, 3-methylisoxazole-5-carboxylic acid.
    Pereira JN, Holland GF.
    J Pharmacol Exp Ther; 1967 Aug; 157(2):381-7. PubMed ID: 6039829
    [No Abstract] [Full Text] [Related]

  • 23. Management of hyperlipidemia: goals for the prevention of atherosclerosis.
    Illingworth DR.
    Clin Invest Med; 1990 Aug; 13(4):211-8. PubMed ID: 2208837
    [Abstract] [Full Text] [Related]

  • 24. [Clofibrate therapy--the status quo].
    Reuter W.
    Z Gesamte Inn Med; 1982 Jan 15; 37(2):59-63. PubMed ID: 7080553
    [Abstract] [Full Text] [Related]

  • 25. [Insulinemia, fatty acids in plasma lipids and lipoproteins and oxidation of VLDL and LDL in hyperlipidemia].
    Zeman M, Zák A, Tvrzická E, Buchtíková M, Stípek S, Pousek L.
    Sb Lek; 2000 Jan 15; 101(1):77-82. PubMed ID: 10953635
    [Abstract] [Full Text] [Related]

  • 26. Pathogenic role of abnormal fatty acids and adipokines in the portal flow. Relevance for metabolic syndrome, hepatic steatosis and steatohepatitis.
    Brudaşcă I, Cucuianu M.
    Rom J Intern Med; 2007 Jan 15; 45(2):149-57. PubMed ID: 18333368
    [Abstract] [Full Text] [Related]

  • 27. Regulation of plasma triglycerides in insulin resistance and diabetes.
    Ginsberg HN, Zhang YL, Hernandez-Ono A.
    Arch Med Res; 2005 Jan 15; 36(3):232-40. PubMed ID: 15925013
    [Abstract] [Full Text] [Related]

  • 28. Treatment of hyperlipoproteinemia type II with etofibrate.
    Gustafson A.
    Int J Clin Pharmacol Biopharm; 1979 Dec 15; 17(12):498-502. PubMed ID: 528096
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Modification of nicotinic acid and prostaglandin E1 antilipolytic action in vitro.
    Sutherland WH, Larking PW, Nye ER.
    Atherosclerosis; 1976 Oct 15; 25(1):45-53. PubMed ID: 186078
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) I - Mechanism of action.
    Lovisolo PP, Briatico-Vangosa G, Orsini G, Ronchi R, Angelucci R, Valzelli G.
    Pharmacol Res Commun; 1981 Feb 15; 13(2):151-61. PubMed ID: 6261266
    [No Abstract] [Full Text] [Related]

  • 35. Mechanisms of lipid-lowering agents.
    Sirtori CR, Manzoni C, Lovati MR.
    Cardiology; 1991 Feb 15; 78(3):226-35. PubMed ID: 1868500
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. 5-(3-pyridyl)tetrazole, a potent and long-acting lipolysis inhibitor.
    Holland GF, Pereira JN.
    Experientia; 1967 Feb 15; 23(2):88-9. PubMed ID: 6040484
    [No Abstract] [Full Text] [Related]

  • 38. Nicotinic acid and inhibition of fat mobilizing lipolysis. Present status of effects on lipid metabolism.
    Carlson LA.
    Adv Exp Med Biol; 1978 Feb 15; 109():225-38. PubMed ID: 364948
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.